Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 142 entries
Sorted by: Best Match Show Resources per page
Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

European urology

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ.
PMID: 29306512
Eur Urol. 2018 Apr;73(4):e116-e118. doi: 10.1016/j.eururo.2017.12.016. Epub 2018 Jan 03.

No abstract available.

Cite
Escudier B, Sharma P, McDermott DF, et al. Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. Eur Urol. 2018;73(4):e116-e118doi: 10.1016/j.eururo.2017.12.016.
Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Peltola, K., Wagstaff, J., Gauler, T. C., Ueda, T., Zhao, H., Waxman, I. M., Motzer, R. J. (2018). Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. European urology, 73(4), e116-e118. https://doi.org/10.1016/j.eururo.2017.12.016
Escudier, Bernard, et al. "Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]." European urology vol. 73,4 (2018): e116-e118. doi: https://doi.org/10.1016/j.eururo.2017.12.016
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ. Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. Eur Urol. 2018 Apr;73(4):e116-e118. doi: 10.1016/j.eururo.2017.12.016. Epub 2018 Jan 03. PMID: 29306512.
Copy Download .nbib Format: NLM
Quantitative characterisation of conductive fibers by capacitive coupling.

The Analyst

Ruland A, Jalili R, Mozer AJ, Wallace GG.
PMID: 29119152
Analyst. 2017 Dec 18;143(1):215-223. doi: 10.1039/c7an00442g.

This work presents a study on a capacitively coupled contactless conductivity detector (C4D) for micron-sized fibers. Following a previous report on the qualitative application of C4D for fibers, the present study provides a thorough analysis of the signal response...

Cite
Ruland A, Jalili R, Mozer AJ, et al. Quantitative characterisation of conductive fibers by capacitive coupling. Analyst. 2017;143(1):215-223doi: 10.1039/c7an00442g.
Ruland, A., Jalili, R., Mozer, A. J., & Wallace, G. G. (2017). Quantitative characterisation of conductive fibers by capacitive coupling. The Analyst, 143(1), 215-223. https://doi.org/10.1039/c7an00442g
Ruland, Andres, et al. "Quantitative characterisation of conductive fibers by capacitive coupling." The Analyst vol. 143,1 (2017): 215-223. doi: https://doi.org/10.1039/c7an00442g
Ruland A, Jalili R, Mozer AJ, Wallace GG. Quantitative characterisation of conductive fibers by capacitive coupling. Analyst. 2017 Dec 18;143(1):215-223. doi: 10.1039/c7an00442g. PMID: 29119152.
Copy Download .nbib Format: NLM
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.

Kidney cancer (Clifton, Va.)

Carlo MI, Manley B, Patil S, Woo KM, Coskey DT, Redzematovic A, Arcila M, Ladanyi M, Lee W, Chen YB, Lee CH, Feldman DR, Hakimi AA, Motzer RJ, Hsieh JJ, Voss MH.
PMID: 30334004
Kidney Cancer. 2017 Jul 26;1(1):49-56. doi: 10.3233/KCA-160003.

No abstract available.

Cite
Carlo MI, Manley B, Patil S, et al. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. 2017;1(1):49-56doi: 10.3233/KCA-160003.
Carlo, M. I., Manley, B., Patil, S., Woo, K. M., Coskey, D. T., Redzematovic, A., Arcila, M., Ladanyi, M., Lee, W., Chen, Y. B., Lee, C. H., Feldman, D. R., Hakimi, A. A., Motzer, R. J., Hsieh, J. J., & Voss, M. H. (2017). Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney cancer (Clifton, Va.), 1(1), 49-56. https://doi.org/10.3233/KCA-160003
Carlo, M I, et al. "Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma." Kidney cancer (Clifton, Va.) vol. 1,1 (2017): 49-56. doi: https://doi.org/10.3233/KCA-160003
Carlo MI, Manley B, Patil S, Woo KM, Coskey DT, Redzematovic A, Arcila M, Ladanyi M, Lee W, Chen YB, Lee CH, Feldman DR, Hakimi AA, Motzer RJ, Hsieh JJ, Voss MH. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. 2017 Jul 26;1(1):49-56. doi: 10.3233/KCA-160003. PMID: 30334004; PMCID: PMC6179122.
Copy Download .nbib Format: NLM
Author Correction: Towards individualized therapy for metastatic renal cell carcinoma.

Nature reviews. Clinical oncology

Kotecha RR, Motzer RJ, Voss MH.
PMID: 31024079
Nat Rev Clin Oncol. 2019 Oct;16(10):653. doi: 10.1038/s41571-019-0214-4.

The competing interests section of the HTML and PDF versions of this manuscript originally did not include the research support received by Robert J. Motzer from Eisai. This information has been added to the competing interests section of the...

Cite
Kotecha RR, Motzer RJ, Voss MH. Author Correction: Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol. 2019;16(10):653doi: 10.1038/s41571-019-0214-4.
Kotecha, R. R., Motzer, R. J., & Voss, M. H. (2019). Author Correction: Towards individualized therapy for metastatic renal cell carcinoma. Nature reviews. Clinical oncology, 16(10), 653. https://doi.org/10.1038/s41571-019-0214-4
Kotecha, Ritesh R, et al. "Author Correction: Towards individualized therapy for metastatic renal cell carcinoma." Nature reviews. Clinical oncology vol. 16,10 (2019): 653. doi: https://doi.org/10.1038/s41571-019-0214-4
Kotecha RR, Motzer RJ, Voss MH. Author Correction: Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol. 2019 Oct;16(10):653. doi: 10.1038/s41571-019-0214-4. PMID: 31024079.
Copy Download .nbib Format: NLM
Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing.

European urology oncology

Truong H, Sheikh R, Kotecha R, Kemel Y, Reisz PA, Lenis AT, Mehta NN, Khurram A, Joseph V, Mandelker D, Latham A, Ceyhan-Birsoy O, Ladanyi M, Shah NJ, Walsh MF, Voss MH, Lee CH, Russo P, Coleman JA, Hakimi AA, Feldman DR, Stadler ZK, Robson ME, Motzer RJ, Offit K, Patil S, Carlo MI.
PMID: 34654685
Eur Urol Oncol. 2021 Dec;4(6):993-1000. doi: 10.1016/j.euo.2021.09.005. Epub 2021 Oct 12.

BACKGROUND: Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking.OBJECTIVE: To define the germline genetic spectrum and clinical...

Cite
Truong H, Sheikh R, Kotecha R, et al. Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. Eur Urol Oncol. 2021;4(6):993-1000doi: 10.1016/j.euo.2021.09.005.
Truong, H., Sheikh, R., Kotecha, R., Kemel, Y., Reisz, P. A., Lenis, A. T., Mehta, N. N., Khurram, A., Joseph, V., Mandelker, D., Latham, A., Ceyhan-Birsoy, O., Ladanyi, M., Shah, N. J., Walsh, M. F., Voss, M. H., Lee, C. H., Russo, P., Coleman, J. A., Hakimi, A. A., Feldman, D. R., Stadler, Z. K., Robson, M. E., Motzer, R. J., Offit, K., Patil, S., & Carlo, M. I. (2021). Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European urology oncology, 4(6), 993-1000. https://doi.org/10.1016/j.euo.2021.09.005
Truong, Hong, et al. "Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing." European urology oncology vol. 4,6 (2021): 993-1000. doi: https://doi.org/10.1016/j.euo.2021.09.005
Truong H, Sheikh R, Kotecha R, Kemel Y, Reisz PA, Lenis AT, Mehta NN, Khurram A, Joseph V, Mandelker D, Latham A, Ceyhan-Birsoy O, Ladanyi M, Shah NJ, Walsh MF, Voss MH, Lee CH, Russo P, Coleman JA, Hakimi AA, Feldman DR, Stadler ZK, Robson ME, Motzer RJ, Offit K, Patil S, Carlo MI. Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. Eur Urol Oncol. 2021 Dec;4(6):993-1000. doi: 10.1016/j.euo.2021.09.005. Epub 2021 Oct 12. PMID: 34654685.
Copy Download .nbib Format: NLM
Multisample Correlation Reveals the Origin of the Photocurrent of an Unstable Cu.

The journal of physical chemistry letters

Kim K, Peleckis G, Wagner K, Mozer AJ.
PMID: 34410734
J Phys Chem Lett. 2021 Sep 02;12(34):8157-8163. doi: 10.1021/acs.jpclett.1c02280. Epub 2021 Aug 19.

The reliable characterization of the photoelectrochemical (PEC) performance of unstable photoelectrodes, often the simplest devices used as a baseline, is a huge challenge. By performing a correlation analysis of more than 100 parameters of Cu

Cite
Kim K, Peleckis G, Wagner K, et al. Multisample Correlation Reveals the Origin of the Photocurrent of an Unstable Cu. J Phys Chem Lett. 2021;12(34):8157-8163doi: 10.1021/acs.jpclett.1c02280.
Kim, K., Peleckis, G., Wagner, K., & Mozer, A. J. (2021). Multisample Correlation Reveals the Origin of the Photocurrent of an Unstable Cu. The journal of physical chemistry letters, 12(34), 8157-8163. https://doi.org/10.1021/acs.jpclett.1c02280
Kim, Kyuman, et al. "Multisample Correlation Reveals the Origin of the Photocurrent of an Unstable Cu." The journal of physical chemistry letters vol. 12,34 (2021): 8157-8163. doi: https://doi.org/10.1021/acs.jpclett.1c02280
Kim K, Peleckis G, Wagner K, Mozer AJ. Multisample Correlation Reveals the Origin of the Photocurrent of an Unstable Cu. J Phys Chem Lett. 2021 Sep 02;12(34):8157-8163. doi: 10.1021/acs.jpclett.1c02280. Epub 2021 Aug 19. PMID: 34410734.
Copy Download .nbib Format: NLM
Band Alignments, Band Gap, Core Levels, and Valence Band States in Cu.

ACS applied materials & interfaces

Whittles TJ, Veal TD, Savory CN, Yates PJ, Murgatroyd PAE, Gibbon JT, Birkett M, Potter RJ, Major JD, Durose K, Scanlon DO, Dhanak VR.
PMID: 31276370
ACS Appl Mater Interfaces. 2019 Jul 31;11(30):27033-27047. doi: 10.1021/acsami.9b04268. Epub 2019 Jul 18.

The earth-abundant semiconductor Cu

Cite
Whittles TJ, Veal TD, Savory CN, et al. Band Alignments, Band Gap, Core Levels, and Valence Band States in Cu. ACS Appl Mater Interfaces. 2019;11(30):27033-27047doi: 10.1021/acsami.9b04268.
Whittles, T. J., Veal, T. D., Savory, C. N., Yates, P. J., Murgatroyd, P. A. E., Gibbon, J. T., Birkett, M., Potter, R. J., Major, J. D., Durose, K., Scanlon, D. O., & Dhanak, V. R. (2019). Band Alignments, Band Gap, Core Levels, and Valence Band States in Cu. ACS applied materials & interfaces, 11(30), 27033-27047. https://doi.org/10.1021/acsami.9b04268
Whittles, Thomas J, et al. "Band Alignments, Band Gap, Core Levels, and Valence Band States in Cu." ACS applied materials & interfaces vol. 11,30 (2019): 27033-27047. doi: https://doi.org/10.1021/acsami.9b04268
Whittles TJ, Veal TD, Savory CN, Yates PJ, Murgatroyd PAE, Gibbon JT, Birkett M, Potter RJ, Major JD, Durose K, Scanlon DO, Dhanak VR. Band Alignments, Band Gap, Core Levels, and Valence Band States in Cu. ACS Appl Mater Interfaces. 2019 Jul 31;11(30):27033-27047. doi: 10.1021/acsami.9b04268. Epub 2019 Jul 18. PMID: 31276370.
Copy Download .nbib Format: NLM
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Gleeson JP, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S, Ged Y, Kotecha RR, Shapnik N, Murray S, Russo P, Coleman J, Lee CH, Stadler ZK, Hakimi AA, Feldman DR, Motzer RJ, Reznik E, Voss MH, Chen YB, Carlo MI.
PMID: 33658299
Clin Cancer Res. 2021 May 15;27(10):2910-2919. doi: 10.1158/1078-0432.CCR-20-4367. Epub 2021 Mar 03.

PURPOSE: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive form of RCC associated with hereditary leiomyomatosis and RCC syndrome. Evidence for systemic therapy efficacy is lacking.EXPERIMENTAL DESIGN: We studied clinical and genomic characteristics of FH-RCC, including response...

Cite
Gleeson JP, Nikolovski I, Dinatale R, et al. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clin Cancer Res. 2021;27(10):2910-2919doi: 10.1158/1078-0432.CCR-20-4367.
Gleeson, J. P., Nikolovski, I., Dinatale, R., Zucker, M., Knezevic, A., Patil, S., Ged, Y., Kotecha, R. R., Shapnik, N., Murray, S., Russo, P., Coleman, J., Lee, C. H., Stadler, Z. K., Hakimi, A. A., Feldman, D. R., Motzer, R. J., Reznik, E., Voss, M. H., Chen, Y. B., & Carlo, M. I. (2021). Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2910-2919. https://doi.org/10.1158/1078-0432.CCR-20-4367
Gleeson, Jack P, et al. "Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2910-2919. doi: https://doi.org/10.1158/1078-0432.CCR-20-4367
Gleeson JP, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S, Ged Y, Kotecha RR, Shapnik N, Murray S, Russo P, Coleman J, Lee CH, Stadler ZK, Hakimi AA, Feldman DR, Motzer RJ, Reznik E, Voss MH, Chen YB, Carlo MI. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clin Cancer Res. 2021 May 15;27(10):2910-2919. doi: 10.1158/1078-0432.CCR-20-4367. Epub 2021 Mar 03. PMID: 33658299; PMCID: PMC8127353.
Copy Download .nbib Format: NLM
A supramolecular approach to lithium ion solvation at nanostructured dye sensitised inorganic/organic heterojunctions.

Chemical communications (Cambridge, England)

Park T, Haque SA, Potter RJ, Holmes AB, Durrant JR.
PMID: 14680220
Chem Commun (Camb). 2003 Dec 07;(23):2878-9. doi: 10.1039/b306604e.

A novel arylamine based hole transporting material (HTM) with tetraethylene glycol (TEG) side groups is reported. Lithium ions solubilised by the TEG groups are employed to modulate interfacial electron transfer reactions at a dye sensitised TiO2/HTM interface.

Cite
Park T, Haque SA, Potter RJ, et al. A supramolecular approach to lithium ion solvation at nanostructured dye sensitised inorganic/organic heterojunctions. Chem Commun (Camb). 2003;(23):2878-9doi: 10.1039/b306604e.
Park, T., Haque, S. A., Potter, R. J., Holmes, A. B., & Durrant, J. R. (2003). A supramolecular approach to lithium ion solvation at nanostructured dye sensitised inorganic/organic heterojunctions. Chemical communications (Cambridge, England), (23), 2878-9. https://doi.org/10.1039/b306604e
Park, Taiho, et al. "A supramolecular approach to lithium ion solvation at nanostructured dye sensitised inorganic/organic heterojunctions." Chemical communications (Cambridge, England) vol. ,23 (2003): 2878-9. doi: https://doi.org/10.1039/b306604e
Park T, Haque SA, Potter RJ, Holmes AB, Durrant JR. A supramolecular approach to lithium ion solvation at nanostructured dye sensitised inorganic/organic heterojunctions. Chem Commun (Camb). 2003 Dec 07;(23):2878-9. doi: 10.1039/b306604e. PMID: 14680220.
Copy Download .nbib Format: NLM
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.

JAMA oncology

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, Lee JL, Suarez C, Stroyakovskiy D, De Giorgi U, Donskov F, Mellado B, Banchereau R, Hamidi H, Khan O, Craine V, Huseni M, Flinn N, Dubey S, Rini BI.
PMID: 34940781
JAMA Oncol. 2021 Dec 23; doi: 10.1001/jamaoncol.2021.5981. Epub 2021 Dec 23.

IMPORTANCE: Interim analyses of the IMmotion151 trial (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma) reported improved progression-free survival (PFS) for patients with programmed death ligand 1-positive (PD-L1+) metastatic...

Cite
Motzer RJ, Powles T, Atkins MB, et al. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol. 2021;doi: 10.1001/jamaoncol.2021.5981.
Motzer, R. J., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Alekseev, B. Y., Lee, J. L., Suarez, C., Stroyakovskiy, D., De Giorgi, U., Donskov, F., Mellado, B., Banchereau, R., Hamidi, H., Khan, O., Craine, V., Huseni, M., Flinn, N., Dubey, S., & Rini, B. I. (2021). Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA oncology, . https://doi.org/10.1001/jamaoncol.2021.5981
Motzer, Robert J, et al. "Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma." JAMA oncology vol. (2021). doi: https://doi.org/10.1001/jamaoncol.2021.5981
Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, Lee JL, Suarez C, Stroyakovskiy D, De Giorgi U, Donskov F, Mellado B, Banchereau R, Hamidi H, Khan O, Craine V, Huseni M, Flinn N, Dubey S, Rini BI. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol. 2021 Dec 23; doi: 10.1001/jamaoncol.2021.5981. Epub 2021 Dec 23. PMID: 34940781.
Copy Download .nbib Format: NLM
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research

Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF.
PMID: 34759043
Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10.

PURPOSE: Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity may persist. We describe treatment-free survival (TFS), with and without toxicity.PATIENTS AND METHODS: Data were analyzed from the randomized phase...

Cite
Regan MM, Jegede OA, Mantia CM, et al. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res. 2021;27(24):6687-6695doi: 10.1158/1078-0432.CCR-21-2283.
Regan, M. M., Jegede, O. A., Mantia, C. M., Powles, T., Werner, L., Motzer, R. J., Tannir, N. M., Lee, C. H., Tomita, Y., Voss, M. H., Plimack, E. R., Choueiri, T. K., Rini, B. I., Hammers, H. J., Escudier, B., Albiges, L., Huo, S., Del Tejo, V., Stwalley, B., Atkins, M. B., & McDermott, D. F. (2021). Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6687-6695. https://doi.org/10.1158/1078-0432.CCR-21-2283
Regan, Meredith M, et al. "Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6687-6695. doi: https://doi.org/10.1158/1078-0432.CCR-21-2283
Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10. PMID: 34759043.
Copy Download .nbib Format: NLM
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research

Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF.
PMID: 34759043
Clin Cancer Res. 2021 Nov 10; doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10.

PURPOSE: Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity may persist. We describe treatment-free survival (TFS), with and without toxicity.PATIENTS AND METHODS: Data were analyzed from the randomized phase...

Cite
Regan MM, Jegede OA, Mantia CM, et al. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-2283.
Regan, M. M., Jegede, O. A., Mantia, C. M., Powles, T., Werner, L., Motzer, R. J., Tannir, N. M., Lee, C. H., Tomita, Y., Voss, M. H., Plimack, E. R., Choueiri, T. K., Rini, B. I., Hammers, H. J., Escudier, B., Albiges, L., Huo, S., Del Tejo, V., Stwalley, B., Atkins, M. B., & McDermott, D. F. (2021). Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-2283
Regan, Meredith M, et al. "Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-2283
Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res. 2021 Nov 10; doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10. PMID: 34759043.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 142 entries